Cargando…

Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC

Detalles Bibliográficos
Autores principales:	Kong, Lingping, Meng, Fanlu, Wu, Sijin, Zhou, Ping, Ge, Ruixin, Liu, Min, Zhang, Linlin, Zhou, Jun, Zhong, Diansheng, Xie, Songbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884801/ https://www.ncbi.nlm.nih.gov/pubmed/36710401 http://dx.doi.org/10.1002/ctm2.1191

Ejemplares similares

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

Degradation of mutant p53H175 protein by Zn(II) through autophagy
por: Garufi, A, et al.
Publicado: (2014)

The Function of the Mutant p53-R175H in Cancer
por: Chiang, Yen-Ting, et al.
Publicado: (2021)

Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
por: Bond, Michael J., et al.
Publicado: (2020)

Plakoglobin restores tumor suppressor activity of p53(R175H) mutant by sequestering the oncogenic potential of β‐catenin
por: Alaee, Mahsa, et al.
Publicado: (2018)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
por: Cantley, Jennifer, et al.
Publicado: (2022)

Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism
por: Zhou, Ge, et al.
Publicado: (2014)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment
por: Zhang, Yuzhu, et al.
Publicado: (2022)

Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
por: Zhang, Lin, et al.
Publicado: (2022)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

LncRNA H19 Promotes Lung Adenocarcinoma Progression via Binding to Mutant p53 R175H
por: Zhou, Yaodong, et al.
Publicado: (2022)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
por: Gasic, Ivana, et al.
Publicado: (2020)

RNA‐PROTACs: Degraders of RNA‐Binding Proteins
por: Ghidini, Alice, et al.
Publicado: (2020)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Single amino acid–based PROTACs trigger degradation of the oncogenic kinase BCR–ABL in chronic myeloid leukemia (CML)
por: Zhang, Jianchao, et al.
Publicado: (2023)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer
por: Zhang, Linlin, et al.
Publicado: (2019)

Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer
por: Zhang, Linlin, et al.
Publicado: (2022)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
por: Pan, Hai, et al.
Publicado: (2023)

Degrading AR-Dependent Cancers: Expanding the Role of PROTACs
por: Michmerhuizen, Anna R., et al.
Publicado: (2020)

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
por: Liu, Jing, et al.
Publicado: (2021)

BacPROTACs mediate targeted protein degradation in bacteria
por: Morreale, Francesca E., et al.
Publicado: (2022)

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
por: Xiao, Mingchao, et al.
Publicado: (2022)

Association of MicroRNA-21 with p53 at Mutant Sites R175H and R248Q, Clinicopathological Features, and Prognosis of NSCLC
por: Zhou, Yaodong, et al.
Publicado: (2020)

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
por: Wang, Huifang, et al.
Publicado: (2023)

Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
por: Zhang, Xiaoyu, et al.
Publicado: (2019)

Structural basis of PROTAC cooperative recognition for selective protein degradation
por: Gadd, Morgan S., et al.
Publicado: (2017)

Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
por: Gabizon, Ronen, et al.
Publicado: (2020)

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
por: Naito, Mikihiko, et al.
Publicado: (2019)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
por: Qi, Si-Min, et al.
Publicado: (2021)

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
por: Alabi, Shanique B., et al.
Publicado: (2021)

Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
por: Yuan, Minghua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bmfbrhevnkcpeb4acnful1eucu